Rocket Pharmaceuticals (RCKT) 10-Q2024 Q3 Quarterly report

Filed: 7 Nov 24, 4:45pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: CRL, goal, issuable, MAA, moved, neutrophil, periodontal, requested, rolling, submission, surpassed

Removed: administer, animal, attain, chemotherapy, conclusively, concomitant, derived, detectable, displayed, essentially, focusing, GLP, GMP, group, Importantly, induction, initiating, Issuer, juncture, lymphoblastic, lymphoma, negligible, optimal, peer, progressively, representative, showing, specimen, statistical, surgical, tolerance, toxicology, tumor, VCN

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

RCKT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Rocket Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2024, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to his knowledge:

the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2024

By:

/s/ Gaurav Shah, MD

Gaurav Shah, MD

Chief Executive Officer and Director

(Principal Executive Officer)

Date: November 7, 2024

By:

/s/ Aaron Ondrey

Aaron Ondrey

Chief Financial Officer

(Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.